Hsbc Holdings PLC Sells 3,110 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Hsbc Holdings PLC cut its Medpace stake by 76.1% in the second quarter, selling 3,110 shares and retaining 977 shares valued at approximately $518,000. Institutional investors collectively own 77.98% of Medpace.
• Medpace reported stronger-than-expected quarterly results, with EPS of $4.25 versus the $3.98 consensus and revenue of $707.33 million, up 17.2% year over year. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
• Insiders sold 134,471 shares worth about $82.2 million over the past three months, while analysts maintain a consensus “Hold” rating with an average price target of $595.20.

Hsbc Holdings PLC trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 76.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 977 shares of the company's stock after selling 3,110 shares during the period. Hsbc Holdings PLC's holdings in Medpace were worth $518,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Medpace in the second quarter worth $1,323,047,000. Geode Capital Management LLC lifted its position in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock worth $374,836,000 after purchasing an additional 24,625 shares during the period. Wasatch Advisors LP lifted its position in shares of Medpace by 19.4% in the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company's stock worth $371,634,000 after purchasing an additional 125,625 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Medpace by 8.3% during the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company's stock valued at $242,337,000 after purchasing an additional 38,760 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Medpace by 19.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company's stock valued at $210,637,000 after purchasing an additional 60,883 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 650 shares of the firm's stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $620.27, for a total transaction of $403,175.50. Following the completion of the sale, the chief executive officer directly owned 539,894 shares in the company, valued at approximately $334,880,051.38. This trade represents a 0.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the firm's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director owned 27,825 shares of the company's stock, valued at approximately $16,935,129.75. This represents a 15.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 134,471 shares of company stock valued at $82,151,311. Insiders own 20.50% of the company's stock.

Medpace Stock Performance

MEDP stock opened at $595.41 on Tuesday. The firm has a 50 day moving average price of $579.61 and a 200-day moving average price of $506.17. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm has a market capitalization of $16.62 billion, a price-to-earnings ratio of 34.90, a PEG ratio of 2.62 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm's quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on MEDP shares. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Weiss Ratings upgraded Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Robert W. Baird upped their price target on Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research note on Friday, July 24th. BMO Capital Markets increased their price objective on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a report on Friday, July 24th. Finally, Leerink Partners set a $620.00 price objective on Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $595.20.

Medpace Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.